Zydus Lifesciences Secures 99.89% Shareholder Approval for ₹5,000 Crore Fundraising

Zydus Lifesciences Limited , a prominent player in the pharmaceutical industry, has successfully secured overwhelming shareholder approval for its ambitious ₹5,000 crore fundraising initiative through a postal ballot process conducted on December 12, 2025.

Postal Ballot Results

The company announced comprehensive results of its postal ballot exercise, with shareholders demonstrating strong confidence in the fundraising proposal. The voting was conducted entirely through remote e-voting in compliance with the Companies Act, 2013 and relevant regulatory guidelines.

Voting Details:	Results
Total Valid Votes:	92,41,41,736
Votes in Favor:	92,31,41,736 (99.89%)
Votes Against:	9,91,084 (0.11%)
Voting Method:	Remote e-voting only

The remote e-voting period was conducted from November 13, 2025 (9:00 AM IST) to December 12, 2025 (5:00 PM IST), with Mr. Ashish Doshi of SPANJ Associates serving as the appointed scrutinizer for the voting process. The postal ballot notice was circulated to shareholders on November 11, 2025, with the cut-off date set as November 7, 2025.

Approved Fundraising Framework

The special resolution approved by shareholders provides comprehensive authorization for the Board of Directors to raise funds through multiple instruments and methods. The approved framework allows for significant flexibility in execution.

Fundraising Parameters:	Details
Maximum Amount:	₹5,000 crores
Securities Types:	Equity shares, non-convertible debentures with warrants, convertible securities
Issuance Methods:	QIP, rights issue, preferential allotment, private placement
Completion Timeline:	Within 365 days from resolution date

Fund Utilization Strategy

The company has outlined a strategic approach for utilizing the raised funds, focusing on strengthening its financial position and supporting growth initiatives across multiple areas.

Fund Utilization:	Purpose
Debt Management:	Prepayment of outstanding borrowings
Growth Initiatives:	Organic and inorganic expansion opportunities
Capital Investment:	Infrastructure and facility expansion
General Purposes:	As permitted under applicable laws

NMPA Approval in China

In addition to the fundraising success, Zydus Lifesciences has received approval from China's National Medical Products Administration (NMPA) for Venlafaxine Extended-Release (ER) Capsules in 75 mg and 150 mg strengths. This marks the company's first approval from the NMPA in China, potentially opening up new market opportunities.

Product Details:	Specifications
Product:	Venlafaxine ER Capsules
Strengths:	75 mg and 150 mg
Manufacturing Facility:	Moraiya, Ahmedabad
Market:	China (First NMPA approval)

Venlafaxine ER Capsules are indicated for treating Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). The medication works by restoring the balance of serotonin and norepinephrine in the brain.

These developments showcase Zydus Lifesciences' commitment to expanding its financial capabilities and global market presence, positioning the company for future growth and innovation in the pharmaceutical sector.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.81%	-0.32%	-1.41%	-5.42%	-6.70%	+97.41%

Zydus Life Science , a prominent Indian pharmaceutical company, has achieved a significant milestone in its global expansion efforts. The company has received its first approval from China's National Medical Products Administration (NMPA) for Venlafaxine Extended-Release Capsules, marking a crucial step into the Chinese pharmaceutical market.

Key Highlights

Product Approved: Venlafaxine Extended-Release Capsules
Strengths: 75mg and 150mg
Approving Authority: China's National Medical Products Administration (NMPA)
Therapeutic Use: Treatment of major depressive disorder and anxiety disorders

Significance of the Approval

This approval represents Zydus Lifesciences' first entry into the Chinese pharmaceutical market through the NMPA regulatory pathway. It opens up new opportunities for the company in one of the world's largest healthcare markets.

About the Medication

Venlafaxine is an antidepressant belonging to a class of medications called serotonin-norepinephrine reuptake inhibitors (SNRIs). The extended-release formulation allows for once-daily dosing, which may improve patient compliance.

Aspect	Details
Drug Name	Venlafaxine Extended-Release Capsules
Approved Strengths	75mg and 150mg
Primary Indications	Major depressive disorder, Anxiety disorders
Dosage Form	Extended-release capsules

Market Implications

This approval may potentially strengthen Zydus Lifesciences' position in the global pharmaceutical industry. The Chinese market, with its large population and growing healthcare needs, presents a significant opportunity for the company to expand its international presence and potentially increase its revenue streams.

While the financial impact of this approval is yet to be determined, it represents a strategic move for Zydus Lifesciences in its global expansion plans. The company's ability to meet the stringent regulatory requirements of the NMPA also speaks to its capabilities in drug development and manufacturing.

As Zydus Lifesciences continues to expand its global footprint, investors and industry observers will likely keep a close watch on how this approval translates into market performance and future opportunities in the Chinese pharmaceutical landscape.